What the PCOS name change could mean for weight loss support

PCOS is now known as 'PMOS'. Discover how the name change could impact weight management and treatment.

The condition known as 'polycystic ovary syndrome' (PCOS) has long been one of the most misunderstood hormonal conditions affecting women and people assigned female at birth.

Despite the name, many people with PCOS do not actually have any ovarian cysts. Many, too, experience symptoms that extend far beyond reproductive health. These symptoms can include insulin resistance, weight gain, fatigue, acne, excess hair growth, irregular periods and increased long-term metabolic risk.

This mismatch between the name and the lived reality of the condition led to a major clinical decision to change its name.¹

The new name is 'polyendocrine metabolic ovarian syndrome', or PMOS – a name chosen to better reflect the hormonal and metabolic nature of the condition.

This new terminology and the wider conversation surrounding it are important. It signals a growing understanding that PMOS is more than simply a fertility issue or a condition defined by ovarian cysts alone.

For many people living with the condition, that shift in understanding could also have important implications for weight loss treatment and long-term support.

PMOS: not just ovarian cysts

The name 'polycystic ovary syndrome' could often be misleading.

While some people with PMOS do develop multiple small follicles on the ovaries, not everybody does. Equally, the presence of ovarian cysts alone does not necessarily mean a person has the condition.

Diagnosis is usually based on a combination of symptoms and clinical findings, as well as polycystic ovarian appearance. Clinicians might look for:

• Irregular, missed or absent periods
• Signs of elevated androgen hormones
• Acne
• Hirsutism (excess hair growth)
• Insulin resistance
• Weight gain or difficulty losing weight
  
  

That's why the name 'polycystic ovary syndrome' oversimplifies what is actually a complex endocrine and metabolic disorder.

The name 'polyendocrine metabolic ovarian syndrome' places greater emphasis on the broader hormonal and metabolic dysfunction involved.

Why weight gain is so common with PMOS

For many people, one of the most frustrating aspects of PMOS is the tendency toward weight gain or difficulty losing weight.

PMOS is strongly associated with insulin resistance, a condition where the body becomes less responsive to the effects of insulin.

Insulin is a hormone involved in regulating blood sugar and energy storage. When insulin resistance develops, the body often compensates by producing more of it.

Higher insulin levels can contribute to:

• Increased hunger and cravings
• Greater fat storage
• Blood sugar instability
• Fatigue and energy fluctuations
• Difficulty maintaining weight loss
  
  

This can create a cycle where traditional dieting approaches feel particularly difficult to sustain.

While weight loss is still biologically possible, the process may genuinely be harder compared with someone without the same hormonal and metabolic challenges.

Why the name change is important

Historically, discussions about the condition focused on fertility and reproductive symptoms, while metabolic health received less attention.

However, research increasingly shows that PMOS affects multiple systems throughout the body.

People with PMOS may face increased risks of:

• Insulin resistance²
• Type 2 diabetes²
• Cardiovascular disease²
• High cholesterol²
• Sleep problems³
• Mental health difficulties⁴
• Weight-related complications²
  
  

Recognising the condition as a wider metabolic syndrome may help encourage more holistic treatment approaches rather than narrowly focusing on ovarian symptoms alone.

For many patients, that recognition no doubt feels validating.

Weight loss with PMOS

The mechanics of weight loss are often presented very simply: eat less, move more.

While energy balance still matters biologically, real-world weight management is influenced by hormones, appetite regulation, stress, sleep, mental health, medication, environment and metabolic adaptation.

PMOS can affect many of these factors simultaneously.

Insulin resistance can increase hunger and cravings, while fatigue and disrupted sleep can make physical activity feel harder to maintain consistently.

Repeated cycles of restrictive dieting can also affect emotional well-being and relationships with food over time.

This is why many clinicians now advocate for more compassionate, realistic approaches to PMOS-related weight management.

Lifestyle support

Despite the hormonal challenges associated with PCOS, lifestyle support remains extremely important.

Sustainable approaches often focus on:

• Balanced nutrition
• Protein and fibre intake
• Physical activity
• Sleep and stress management
• Behavioural support
• Gradual, maintainable habit change
  
  

Extreme or crash dieting approaches sometimes worsen the cycle of restriction, cravings and frustration that many people with PMOS already experience.

A more supportive and realistic approach is usually more sustainable long-term.

Medical support

Weight loss medications like Wegovy and Mounjaro affect appetite regulation, fullness and blood sugar control.

For people with PMOS who experience difficulties with appetite, cravings or repeated cycles of weight regain, these treatments may offer additional support alongside lifestyle changes.

Many people report improvements in appetite control, portion regulation and consistency in weight management.

In clinical trials:

• Mounjaro users lost around 21% of their starting body weight over 72 weeks.⁵
• Wegovy users lost around 15% over 68 weeks.⁶

Although these studies were not designed specifically around people with PMOS, the metabolic mechanisms involved are highly relevant to many living with the condition.

PMOS may impact treatment eligibility

PMOS is often considered during private weight loss treatment assessments because it is associated with a range of metabolic and weight-related health risks.

In some cases, the presence of obesity-related comorbidities can affect eligibility for treatment. For example, certain weight loss medications may be prescribed at lower BMI thresholds when a patient also has a clinically relevant condition linked to excess weight.

While individual assessment processes vary between providers, PMOS is increasingly recognised as part of a broader metabolic health picture rather than simply a reproductive condition.

The importance of compassionate care

One of the most important aspects of the PMOS conversation is the potential for greater empathy and understanding.

Many people living with this condition spend years feeling dismissed, blamed or misunderstood when struggling with weight, fatigue or hormonal symptoms.

A more modern understanding of the condition acknowledges that these challenges are not simply about motivation or self-control.

Biology, hormones and metabolic health all have an impact.

That's not to say that people living with PMOS are powerless. However, it does mean they deserve more nuanced and supportive care than simplistic messaging around dieting and weight loss.

Ultimately, whatever name this condition takes, a better understanding of the metabolic implications of PMOS can only be a good thing. It represents a positive step forward for those living with the condition who are looking to access holistic medical care.

Are you living with PMOS and considering medical support to lose weight? Learn more about PMOS weight loss treatments or take Semapen's digital consultation to find out if you're eligible for our guided programmes.

Sources

1. Teede, H.J. et al. (2026) "Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process" The Lancet. Advance online publication. https://doi.org/10.1016/S0140-6736(26)00717-8

2. Lim, S.S. et al. (2012) "Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis" Human Reproduction Update, 18(6) https://doi.org/10.1093/humupd/dms030

3. Fernandez, R.C. (2018) "Sleep disturbances in women with polycystic ovary syndrome: prevalence, pathophysiology, impact and management strategies" Nature and Science of Sleep, 10:45–64 https://doi.org/10.2147/NSS.S127475

4. Cooney, L.G. (2017) "High prevalence of moderate and severe depressive and anxiety symptoms in polycystic ovary syndrome: a systematic review and meta-analysis" Human Reproduction (Oxford, England), 32(5) https://doi.org/10.1093/humrep/dex044

5. Jastreboff, A.M. et al. (2022) "Tirzepatide Once Weekly for the Treatment of Obesity" The New England Journal of Medicine, 387(3) https://doi.org/10.1056/NEJMoa2206038

6. Wilding, J.P.H. et al. (2021) "Once-Weekly Semaglutide in Adults with Overweight or Obesity" The New England Journal of Medicine, 384(11) https://doi.org/10.1056/NEJMoa2032183

This article was reviewed and approved by Lujain Alhassan, Bariatric Nutritionist, on 1 June 2026.